Mexican Pharma Roundup: February 2020
Below is a selection of top recent news from Mexican pharma and healthcare, including the healthcare reforms president Andres Manuel Lopez Obrador is prioritising, latest news on the INSABI program,…
The National Institute of Psychiatry Ramón de la Fuente is a decentralized public institution part of the system of National Institutes of Health in Mexico. Founded in 1976 the functions of the Institute are: to conduct scientific research, to instruct qualified personnel to conduct these investigations, to train professionals and technicians in these fields, to treat psychiatric patients and to act as an advisor to other official and private organisms. The Institute participates in the development of health policies by coordinating with institutions at national level with both the government and civil society, by helping in the adoption of new policies in the areas of mental health and substance abuse in its role as member of the National Council against Addictions and organism in charge of mental health in the country. Since 1976 the Institute has been designated as a WHO/PAHO Collaborating Centre and been continuously re-designated every four years until 2015. The Institute possesses three research branches― neuroscience, clinical, epidemiological, and psychosocial research — an education office and an area of clinical services.
Below is a selection of top recent news from Mexican pharma and healthcare, including the healthcare reforms president Andres Manuel Lopez Obrador is prioritising, latest news on the INSABI program,…
Between 2015 and 2017 PharmaBoardroom met with pharma country managers in Mexico who spoke about the challenges and opportunities present in the Mexican market. Since then, these five stakeholders have…
The United States Trade Representative Office has been engaging with a number of countries, including Mexico, to address concerns related to IP protection and enforcement and market access barriers for…
What traits, competencies and drivers do you need to be a successful pharma country manager in today’s dynamic Mexican pharma market? Jose Guerrero and Male Mejido from the Mexico office…
Cristobal Thompson of the AMIIF examines the steps forward that Mexican pharma has made in countering corruption, the areas in which urgent improvement is still needed, and outlines the three…
Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). In this article, he introduces us to an exciting new youth program set up to improve…
Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health…
David Peña Castillo, president and founder of the Mexican Federation of Rare Diseases (FEMEXER), addresses the problem of patients deserting therapies. In Mexico, approximately 15 percent of patients treated…
Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health…
Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health…
Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving…
David Peña Castillo is the President and founder of The Mexican Federation of Rare Diseases (FEMEXER). Here he discusses what makes a patients association. When we find a way to…
See our Cookie Privacy Policy Here
